Company Overview of Pierre Fabre S.A.
Pierre Fabre S.A. designs, develops, produces, and markets pharmaceutical products for customers in France and internationally. The company offers prescription drugs for various treatment fields, such as urology, gynecology, diabetes, cardiology, neuropsychitry, rheumatology, and pneumo-allergology, as well as onco-hematology/oncology and dermatology to health care professionals and their patients. It also provides a range of prescription and over-the-counter drugs for various therapeutic areas, as well as day-to-day general health care, including oral care and natural health care to pharmacists, health care professionals, and patients. In addition, the company offers skin care and hair care...
12 Avenue Hoche
Founded in 1951
Key Executives for Pierre Fabre S.A.
Group Chief Executive Officer, Member of Supervisory Board, Member of Audit Committee, Member of Nomination & Remuneration Committee and Member of Strategic Committee
Senior Vice-President of Finance & Operations
Chief Executive Officer of Pharmaceuticals Division
Chief Executive Officer of Dermo-Cosmetics Division
Compensation as of Fiscal Year 2016.
Pierre Fabre S.A. Key Developments
Array BioPharma Inc. and Pierre Fabre Announce Top-Line Results from Part 1 of the Phase 3 COLUMBUS
Sep 26 16
Array BioPharma Inc. and Pierre Fabre have jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS (Combined LGX818 Used with MEK162 in BRAF Mutant Unresectable Skin Cancer) study evaluating LGX818 (encorafenib), a BRAF inhibitor, and MEK162 (binimetinib), a MEK inhibitor, in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The study met its primary endpoint, significantly improving progression free survival (PFS) compared with vemurafenib, a BRAF inhibitor, alone. In the analysis of the primary endpoint, the median PFS for patients treated with the combination of encorafenib plus binimetinib ("combination") was 14.9 months versus 7.3 months for patients treated with vemurafenib; HR (0.54), [95% CI 0.41-0.71], p<0.001. The combination was generally well-tolerated and reported adverse events were overall consistent with previous combination encorafenib plus binimetinib clinical trial results in BRAF-mutant melanoma patients. Analysis of a secondary endpoint comparing the PFS of patients treated with combination to patients treated with encorafenib showed a median of 14.9 months versus 9.6 months with HR (0.75), [95% CI 0.56-1.00], p=0.051, which did not reach statistical significance. A complete analysis of these results will be provided to global regulatory authorities as part of planned submissions. In addition, data from Part 2 of the COLUMBUS trial are anticipated in mid 2017 and will also be provided to global health authorities as part of planned regulatory submissions for approval of these product candidates. Further results from Part 1 of the COLUMBUS trial, including objective response rates, disease control rates, safety endpoints, exploratory analyses such as a Part 1 PFS comparison of encorafenib to vemurafenib and pre-specified subgroup analyses including outcomes in patients who received prior treatment with immunotherapy will be presented at an upcoming medical meeting. Analysis of the secondary endpoint of overall survival (OS) was not planned as part of these initial results.
Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt Announce Phase 3 BEACON CRC Trial
Jun 4 16
Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt jointly initiated the BEACON CRC (Binimetinib, Encorafenib And Cetuximab Combined to treat BRAF-mutant Colorectal Cancer) trial, a randomized, global Phase 3 clinical trial designed to assess the safety and efficacy of binimetinib (MEK inhibitor), encorafenib (BRAF inhibitor) and Erbitux (monoclonal antibody) in comparison to Erbitux and irinotecan-based therapy in patients with BRAF-mutant colorectal cancer (BRAFm CRC). The primary endpoint is overall survival (OS) and key secondary endpoints include progression-free survival (PFS) and objective response rate (ORR).
Evotec AG Announces the Multi-Year Compound Management Agreement with Pierre Fabre Laboratories
Apr 19 16
Evotec AG announced a multi-year compound management agreement with Pierre Fabre Laboratories. Under the terms of the agreement, Evotec will manage Pierre Fabre's compound collection (individual compounds and collection plates) out of its compound management facility in Toulouse, France. The agreement covers an initial period of five years.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|